论文部分内容阅读
目的研究曼月乐治疗围绝经期妇女功能失调性子宫出血(PDUB)的疗效。方法抽选2013年6月至2014年7月英德市妇幼保健院收治的PDUB患者136例,随机数字表法分为对照组和观察组,每组68例,所有患者在诊刮后第5天给予米非司酮口服治疗,持续用药3个月,观察组患者在上述治疗基础上于诊刮后第5天宫内放置曼月乐。所有患者治疗后每3个月复诊1次,比较两组患者治疗前后月经量、子宫内膜厚度、血红蛋白差异,观察不良反应情况。结果观察组治疗后3个月有效率(70.6%)高于对照组(51.5%),治疗后6个月有效率(91.2%)显著高于对照组(69.1%),差异均有统计学意义(P<0.05);观察组治疗后3、6个月子宫内膜厚度[(5.21±1.58)、(3.51±1.01)mm]明显小于对照组[(6.65±1.43)、(7.04±1.42)mm],差异有统计学意义(P<0.05);观察组治疗后3、6个月静脉血血红蛋白量[(105.81±11.13)、(111.26±12.38)g/L]显著高于对照组[(101.02±10.36)、(107.41±12.34)g/L],差异有统计学意义(P<0.05);两组患者均未见严重不良反应,治疗后3个月两组患者肝肾功能、尿常规均正常。结论曼月乐治疗围绝经期妇女功能失调性子宫出血疗效好,安全性高,值得推广。
Objective To study the efficacy of Mirena in the treatment of dysfunctional uterine bleeding in perimenopausal women (PDUB). Methods A total of 136 patients with PDUB admitted in Yingde Maternal and Child Health Hospital from June 2013 to July 2014 were randomly divided into control group and observation group with 68 cases in each group. Day to give mifepristone oral treatment, continuous medication for 3 months, the observation group patients on the basis of the above treatment in the first 5 days after the curettage placed Mirena. All patients were followed up every 3 months after treatment. The menstrual flow, endometrial thickness and hemoglobin before and after treatment were compared between two groups to observe the adverse reactions. Results The effective rate (70.6%) in observation group at 3 months after treatment was significantly higher than that in control group (51.5%), and the effective rate at 6 months (91.2%) was significantly higher than that of control group (69.1%) (5.21 ± 1.58), (3.51 ± 1.01) mm] in the observation group were significantly lower than those in the control group [(6.65 ± 1.43), (7.04 ± 1.42) mm ], The difference was statistically significant (P <0.05). The hemoglobin in the observation group was significantly higher than that in the control group [(105.02 ± 11.13), (111.26 ± 12.38) g / L] ± 10.36), (107.41 ± 12.34) g / L, respectively. There was no significant difference between the two groups (P <0.05). No significant adverse reactions were observed in both groups. normal. Conclusion Mirena treatment of perimenopausal dysfunctional uterine bleeding in women with good efficacy, high safety, it is worth promoting.